

Guidance on the Management of Patients who are taking Anticoagulants or Antiplatelet Drugs and Require Dental Treatment – Consultation Feedback
Scottish Dental Clinical Effectiveness Programme
Dental Council members of February 2015
9 th March 2015



SDCEP is following a rapid process to develop this guidance, including a short consultation period of four weeks. Consultation is the opportunity for anyone with an interest in the guidance to provide feedback and influence its development. We welcome your views on this draft guidance as part of the formal consultation process, which aims to ensure that the guidance will be appropriate for dental healthcare in Scotland. Please complete this form and submit using the 'Submit' button. Alternatively, you can print this form and return by post or by email as an

attachment.

Please return your form before 9th March 2015 to:

Email: scottishdental.cep@nes.scot.nhs.uk

Tel: 01382 740992

Freepost

Licence RSSH-ETXY-ZKBL

SDPBRN (Anticoagulants Consultation)

Dundee Dental Education Centre, Frankland Building

Small's Wynd, Dundee, DD1 4HN

Name: Laura Mitchell, Honorary Secretary	Profession/ Organisation: Dental Faculty, Royal College of Physicians
Title:	Specific interest in topic:
Telephone: 0141 221 6072	Address: 232-242 St Vincent Street, Glasgow, G2 5RJ
Email address: lyn.cranwell@rcpsg.ac.uk	

For each question, please indicate your response by selecting the appropriate answer or number on the scale. Please provide comments to explain your answer or suggestions for improvement, as appropriate.

1. Overall Impressions

Please indicate the extent to which you agree with the following statements and provide an explanation to support

your answer where possible.		
The information is in a readily accessible form (e.g. with respect to language and layout).	Strongly disagree	1 2 3 4 5 Strongly agree
Explanation:		
The guidance recommendations are clear.	Strongly disagree	1 2 3 4 5 Strongly agree
Explanation:		
The guidance recommendations are acceptable.	Strongly disagree	1 2 3 4 5 Strongly agree
Explanation: Recommendation regarding treating patients with INR <4 NHSGG&C guidance uses INR 3.5	accords with	n NPSA guidance

2. Guidance

Please indicate the extent to which you agree with the following statements and provide an explanation to support your answer where possible. Please note that 'adequately covers' suggests that sufficient information is provided and the information is relevant and helpful.

Section 1 (Introduction) adequately covers the background to the guidance	Strongly disagree	$\begin{vmatrix} 1 & 2 \\ 0 & 0 \end{vmatrix}$	3	4 5 O	Strongly agree
Explanation:					
Section 2 adequately covers the background to the anticoagulants and antiplatelet drugs	Strongly disagree	1 2 O O	3	4 5	Strongly agree
Explanation:					
Section 3 (including the categorisation of procedures in Table 1) adequately covers assessing bleeding risk	Strongly disagree	1 2 O O	3	4 5 O O	Strongly agree
Explanation:	§				
? IDB as unlikely to cause bleeding. Low risk in this conte	ext but of conc	ern in those	with ble	eeding diffi	culties
Section 4 adequately covers general advice for managing bleeding risk	Strongly disagree	1 2 O O	3	4 5 • O	Strongly agree
Explanation:					
Section 5 adequately covers treating a patient taking warfarin or other vitamin K antagonists	Strongly disagree	$ \begin{array}{c c} 1 & 2 \\ O & O \end{array} $	3 (4 5 • O	Strongly agree
Explanation:	•				
Recommendation regarding treating patients with INR <4 NHSGG&C guidance uses INR 3.5	accords with	NPSA guida	nce		
This sac galdanic ases Into 3.5					

Section 6 adequately covers treating a patient taking an antiplatelet drug(s)	Strongly disagree		2	3	4	5	Strongly agree
Explanation:							-
Section 7 adequately covers treating a patient taking one of the newer oral anticoagulants	Strongly disagree		²	3	4 O	5	Strongly agree
Explanation:	253W 28KA 102R N 10			To the 10	-		
Advise practitioner to consult with prescribing practitioner	if patient is to	be ad	vised	to inte	errupt	NOAC	
							×
Section 8 adequately covers treating a patient taking an injectable anticoagulant	Strongly disagree		2	3	4	5	Strongly agree
Explanation: To avoid confusion would it be worth a footnote regarding	g heparin and t	hose o	on dia	lysis, (or per	haps j	ust a note
confirming the difference between heparin and the LMWH	ls?						
5							
Section 9 adequately covers drug prescribing for patients taking anticoagulants and antiplatelet	Strongly	1	2	3	4	5	Strongly
medications	disagree				0		agree
Explanation:							

3. Appendices

Please indicate how useful you think the following appendices are. Where possible, please provide explanations to support your answers (e.g. comment on the level of detail, whether the information is adequate, if not useful, why not?).

Appendix 1 Guidance development	Not at all useful	$\overset{1}{\bigcirc}$	² O	3	4	5	Extremely useful
Appendix 2 Anticoagulant and antiplatelet drugs available in the UK	Not at all useful	$\stackrel{1}{\bigcirc}$	² O	3	4	5	Extremely useful
Appendix 3 Indications for anticoagulation or antiplatelet therapy	Not at all useful	$\overset{1}{\bigcirc}$	2	3	4	5	Extremely useful
Appendix 4 Drug interactions	Not at all useful	$\overset{1}{\bigcirc}$	2	3	4	5	Extremely useful
Appendix 5 Patient Information Leaflet	Not at all useful		² O	3	⁴ O	5	Extremely useful
Appendix 6 Advice for prescribers and dispensers of anticoagulants and antiplatelet drugs	Not at all useful		2	3	4	5	Extremely useful
Appendix 7 Local contacts for advice and referral	Not at all useful		2	3	4	5	Extremely useful
Appendix 8 Summary guidance	Not at all useful	$\overset{1}{\bigcirc}$	² O	3	4	5	Extremely useful
Explanations and comments (please indicate which Appendix): The PiL is clear. However it is quite dense and potentially a daunting read for some individuals. It is a good leaflet for those who manage to read it. We wondered if the post op instructions, while they may give reassurance, could simply say "you dentist will advise you of any special care you require to take after dental treatment" or							
4. Additional Content Do you think any additional information should	Yes			No	1500		Unsure
4. Additional Content Do you think any additional information should be included within the guidance?	Yes			No O	***		Unsure
Do you think any additional information should				0			
Do you think any additional information should be included within the guidance?				0	***		
Do you think any additional information should be included within the guidance? Explanation:		1	² O	0	4 O	5 O	
Do you think any additional information should be included within the guidance? Explanation: 5. Guidance Development How confident are you in the manner in which	Not at all	1 O	²	3	4	5 O	Extremely
Do you think any additional information should be included within the guidance? Explanation: 5. Guidance Development How confident are you in the manner in which the guidance has been developed? (Appendix 1)	Not at all	1 O	² O	3	4 O	5 O	Extremely
Do you think any additional information should be included within the guidance? Explanation: 5. Guidance Development How confident are you in the manner in which the guidance has been developed? (Appendix 1) Explanation: How clear are the differences in the strength of	Not at all confident Not at all	1 O	0	3 ()	4 O	0	Extremely confident Extremely

6. Dissemination

If you think that you will use the guidance when it is published, please indicate how useful you would find each of the following options for dissemination (Note: all guidance products will also be available online to view, download and print):

Printed copies of the full guidance (A4 ~24	Not at all	1	2	3	4	5	Extremely
pp) and summary (A5 4-6 pp) posted to you.	useful	0	0	0	O		useful
Printed summary only posted to you	Not at all useful		2	3	4	5	Extremely useful
Explanation:							
		_					
How important do you think it is for the patient	Not at all	1	2	3	4	5	Extremely
information leaflet to be distributed to patients by the prescriber/dispenser of their medication?	important	0	0	0	0	O	important
	a which this co	uld be	achie	mod:			
If you think that this is important, please suggest ways in Given by GMP or pharmacist backed up by verbal advice.		ulu be	acili	eveu.			
Given by GMP or pharmacist backed up by verbar device.							
7. Impact and Implementation							
Please answer these questions as if the guidance v	vill be publisl	ned ir	its c	urrer	t for	m:	
How confident are you that the guidance could	Not at all	1	2	3	4	5	Extremely
be fully implemented?	confident	0	O	0	O	O	confident
Explanation:							
The summary is vital in order to diseminate the informati	ion particularly	to bu	sy GD	Ps			
	T			T -	1 .	T -	
How difficult would it be to fully implement the	Not at all	$\begin{vmatrix} 1 \\ 0 \end{vmatrix}$	$\frac{2}{0}$	3	4	5	Extremely difficult
guidance?	difficult	O				U	difficult
Explanation:	lastian via be	anlth h	aarda	and I	ocal a	rounc	
It would be important to have launch events and commu	INICALION VIA N	diui L	oarus	anu i	ocai y	Toups	
What might prevent implementation of the guidance?							
Explanation:							
Confidence							
Unwillingness to contact the medical practitioner							

What might help implementation of the guidance?						
Explanation: Importance of launch events and communication via health boards and local groups						
Are there any specific training needs associated with implementation of the guidance?	Yes		No O	Unsure		
If yes, please give details: Read the appendices						
If you are in practice, would you intend to change your current practice in line with the guidance?	Yes		No O	Unsure		
Explanation: Practice with NOACs has been clarified.						
If you are in practice, are there any recommendations you would not intend to implement?	Yes		No O	Unsure		
Explanation: See disparity between guidance and NHS GG&C policy on Warfarin.						
How helpful do you think this guidance would be in primary care dental practice?	Not at all helpful	$ \begin{array}{c c} 1 & 2 \\ O & O \end{array} $	3 4	5 Extremely helpful		
Explanation:	я					

8. Equality

Do you think that any particular equality groups or individuals (guidance users or patients) are likely to be discriminated against by the guidance*?	Yes	No O	Unsure
*i.e. discrimination by age, disability, ethnicity, gender, ge orientation, geographical location or whether a person is a care		ender status, religio	on or belief, sexual
Explanation:			
9. Any Other Comments			
			v

Thank you for taking the time to contribute to this consultation.

Our consultation process aims to be transparent and, on request, we will provide a summary of comments received and our responses. This summary may identify the source of comments received from an organisation or in an official capacity but not those received from individuals.